Clinical Trial Update: BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a BCMA/CD3 bispecific antibody as bridging therapy before CAR-T cell infusion in relapsed or refractory multiple myeloma; curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• BCMA/CD3 bispecific antibody

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Status: NOT_YET_RECRUITING